Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

Tiffany, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Tiffany's Patient Story

Patient Info: Tiffany, Female, Under 40 | Stage IV

Metastatic Site: Pelvis; right femur; cervical spine

As of January 2024, Tiffany’s story described rapid diagnosis of Stage IV lung cancer and evaluation at MD Anderson, with treatment planning underway but specific treatment details not stated.

The Patient Story
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV EGFR-Mutant Lung Adenocarcinoma Responding to Osimertinib

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR L833V/H835L mutations; PD-L1 50%; CDK4 amplification; MDM2 amplification

Metastatic Site: contralateral lung, brain

After 3 months of osimertinib, the right upper lobe lesion had decreased and right hilar lymphadenopathy had resolved. The brain lesion remained stable, and subsequent imaging continued to show improvement in the lung lesion.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Lung cancer first discovered through a skin metastasis

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: skin and subcutaneous tissues; soft tissue and muscle;…

His metastatic disease progressed rapidly, and he died 4.5 months after the initial dermatology referral.

PubMed Central
OutcomeIn Memory
Matt, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV ALK Lung Cancer: Matt's Survivor Story

Patient Info: Matt Hiznay, Male, Under 40 | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: Not reported

As of November 2023, Matt was a 12-year survivor with Stage IV ALK-positive lung cancer in remission, no evidence of disease, and ongoing lorlatinib treatment.

Cleveland Clinic
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Brain radiation therapy complication (radionecrosis) potentially linked to combined chemo-immunotherapy

Patient Info: Anonymized, Female | Stage IV

Biomarkers: PD-L1 0%; tumour mutational burden 33 mutations/Mb; TP53 mutation at diagnosis; later ctDNA included KEAP1 and NOTCH3 alterations

Metastatic Site: brain; presumed leptomeningeal disease

She recovered completely from surgery for radiation necrosis, resumed cancer treatment and remained neurologically intact at 18 months. She was found deceased 9 months later; the cause of death was unknown.

PubMed Central
OutcomeIn Memory
Debra, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Debra's Survivor Story

Patient Info: Debra Haberstroh, Female | Stage I

As of November 2023, Debra was 5 months after May 2023 lung tumor resection, did not need chemotherapy, was described by her oncologist as technically cured, and continued surveillance imaging.

Cleveland Clinic
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV ALK Non-Small Cell Lung Cancer: Christine's Patient Story

Patient Info: Christine, Female, 50s | Stage IV

Biomarkers: ALK mutation / ALK-positive

Metastatic Site: Brain | Liver

As of October 2023, Christine was living with Stage IV ALK-positive NSCLC that remained in check on targeted therapy after alectinib cleared brain and liver spots and lorlatinib continued, with significant chronic side effects.

Lung Cancer Research Foundation
OutcomeLiving With Cancer
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Severe colitis from pembrolizumab immunotherapy requiring additional treatment

Patient Info: Anonymized, Male

Infliximab stopped the bleeding and reduced bowel movements from 11–12 to about 3–4 per day within 1 week, allowing discharge. Continued follow-up was needed for the colitis, hepatitis B reactivation risk and lung cancer.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

BRCA2-Mutated Metastatic Lung Adenocarcinoma Controlled for 30 Months With Olaparib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: PD-L1-negative; BRCA2 mutation; ATM mutation; EGFR-negative; ALK-negative

Metastatic Site: brain

Olaparib provided about 30 months of disease control, and PET imaging remained overall stable when a separate new breast primary was found in February 2023.

PubMed Central
OutcomeStable Disease
Lauren, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Lauren's Survivor Story

Patient Info: Lauren, Female, Under 40 | Stage I

Biomarkers: CD56-positive; neuroendocrine tumor

As of August 2023, Lauren reported no signs of more cancer after bronchoscopy and surgery removing the right lower and middle lung lobes, with surveillance extended to yearly CT scans.

The Patient Story
OutcomeCancer-Free / NED
Lauren, who was diagnosed with Stage I Lung CancerLung Cancer

My Lung Cancer Symptoms: "They Thought it was Asthma!" (Lauren’s Story)

Patient Info: Lauren Koy, Female, Under 40 | Stage I

Biomarkers: No genetic factors reported

As of August 2023, Lauren described lung cancer diagnosis after years of symptoms and surgery to remove part of her lung, then used her story to advocate for being heard despite young age and no smoking history.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 1

Patient Info: Anonymized, Male, 70+

Biomarkers: MET exon 14 skipping mutation

The tumour shrank by 82%; surgery found 5% viable residual tumour and no involved lymph nodes, with postoperative stage ypT2aN0M0. He continued savolitinib without serious adverse effects.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery — Case 2

Patient Info: Anonymized, Female, 60s

Biomarkers: MET exon 14 skipping mutation; PD-L1 expression 75%

Savolitinib produced approximately 72% tumour shrinkage. Surgery found 30% viable residual tumour, negative lymph nodes and ypT1bN0M0 disease; she recovered without complications and continued savolitinib.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

MET-mutated lung cancer: testing savolitinib before surgery

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: MET exon 14 skipping, TP53 and BRAF mutations; PD-L1 expression 5%

Metastatic Site: pleura; mediastinal lymph node

Savolitinib produced a partial radiological response, but surgery confirmed persistent pleural and mediastinal nodal metastases with ypStage IVA disease. He recovered and continued adjuvant savolitinib.

PubMed Central
OutcomeIn Treatment
Terri, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Terri's Survivor Story

Patient Info: Terri Ann DiJulio, Female, 40s | Stage I

Biomarkers: Not reported for patient; family history of lung cancer noted

As of June 2023, Terri Ann was considered no evidence of disease after 3 early-stage lung cancer diagnoses treated with surgery and SBRT, and she had returned to 6-month follow-up while continuing advocacy and cycling.

The Patient Story
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II HR-Positive Lung Cancer: Christine's Survivor Story

Patient Info: Christine, Female | Stage II

Biomarkers: Lung cancer biomarkers not reported; prior breast cancer described as ER-positive, PR-positive, HER2-positive / triple-positive

Reached complete remission from both Stage III triple-positive breast cancer and a separate Stage IIA primary lung cancer after about 1 year, including breast cancer chemotherapy/radiation and lower lung resection.

The Patient Story
OutcomeCancer-Free / NED
Christine, who was diagnosed with Stage II Lung CancerLung Cancer

Stage II Lung Cancer: Christine's Patient Story

Patient Info: Christine, Female, Under 40 | Stage II

As of May 2023, Christine’s lung-cancer story focused on diagnosis of an unexpected Stage IIA lung tumor during breast cancer treatment and the importance of pushing for biopsy when the finding was initially downplayed.

The Patient Story
OutcomeCare Ongoing